Plattet Philippe, Alves Lisa, Herren Michael, Aguilar Hector C
Division of Experimental and Clinical Research, , Vetsuisse Faculty, University of Bern, Bremgartenstrasse 109a, Bern 3001, Switzerland.
Clinical Neurology, Department of Veterinary Medicine, University of Cambridge, CB3 0ES, Cambridge, UK.
Viruses. 2016 Apr 21;8(4):112. doi: 10.3390/v8040112.
Measles virus (MeV), a highly contagious member of the Paramyxoviridae family, causes measles in humans. The Paramyxoviridae family of negative single-stranded enveloped viruses includes several important human and animal pathogens, with MeV causing approximately 120,000 deaths annually. MeV and canine distemper virus (CDV)-mediated diseases can be prevented by vaccination. However, sub-optimal vaccine delivery continues to foster MeV outbreaks. Post-exposure prophylaxis with antivirals has been proposed as a novel strategy to complement vaccination programs by filling herd immunity gaps. Recent research has shown that membrane fusion induced by the morbillivirus glycoproteins is the first critical step for viral entry and infection, and determines cell pathology and disease outcome. Our molecular understanding of morbillivirus-associated membrane fusion has greatly progressed towards the feasibility to control this process by treating the fusion glycoprotein with inhibitory molecules. Current approaches to develop anti-membrane fusion drugs and our knowledge on drug resistance mechanisms strongly suggest that combined therapies will be a prerequisite. Thus, discovery of additional anti-fusion and/or anti-attachment protein small-molecule compounds may eventually translate into realistic therapeutic options.
麻疹病毒(MeV)是副粘病毒科中一种极具传染性的病毒,可导致人类患麻疹。副粘病毒科的负链单股包膜病毒包括几种重要的人类和动物病原体,其中麻疹病毒每年导致约12万例死亡。麻疹病毒和犬瘟热病毒(CDV)介导的疾病可通过接种疫苗预防。然而,疫苗接种效果欠佳持续助长麻疹病毒的爆发。有人提出,使用抗病毒药物进行暴露后预防是一种新策略,可通过填补群体免疫缺口来补充疫苗接种计划。最近的研究表明,麻疹病毒糖蛋白诱导的膜融合是病毒进入和感染的首个关键步骤,并决定细胞病理和疾病结果。我们对麻疹病毒相关膜融合的分子理解在通过用抑制分子处理融合糖蛋白来控制这一过程的可行性方面有了很大进展。目前开发抗膜融合药物的方法以及我们对抗药性机制的了解有力地表明联合治疗将是必要条件。因此,发现更多抗融合和/或抗附着蛋白小分子化合物最终可能转化为切实可行的治疗选择。